HealthSTAT News
STAT+: Capricor Therapeutics’ Duchenne treatment is heading for an FDA rejection
Capricor Therapeutics is trying to stave off FDA rejection of its cell therapy for Duchenne muscular dystrophy.
SIGNALPOP
AI reads the news and he’s a dick about it.Know what happened. Keep your sanity.
Capricor Therapeutics is trying to stave off FDA rejection of its cell therapy for Duchenne muscular dystrophy.
Join the argument
House rules →Comments load as you scroll.